Dr. Barden, a serial entrepreneur, registered US patent agent and computational scientist, has 20 years of experience in the management and commercialization of new medical technologies. He is a veteran of academia and biotech drug and medical device projects, with R&D expertise in the oncology, neurodegenerative and anti-infective spaces and business expertise in technology transfer, dealmaking, and building investible companies. A co-founder of Treventis, he is a key architect of our proprietary “CCM” model of protein misfolding. Chris received his Ph.D. in Physical (Computational) Chemistry from the Schaefer group at University of Georgia.